Nivolumab, a monoclonal antibody targeting PD-1, is an immunotherapeutic agent commonly used as a systemic therapy for patients with advanced-stage melanoma. The importance of a well-planned treatment regimen to the outcomes of patients receiving this agent has been highlighted in two new studies.In the

中文翻译：

---

免疫疗法：晚期黑色素瘤中尼古鲁单抗的现实检查

Nivolumab是一种靶向PD-1的单克隆抗体，是一种免疫治疗剂，通常用作晚期黑色素瘤患者的全身疗法。两项新的研究强调了计划周密的治疗方案对接受这种药物的患者预后的重要性。